Biogen Inc. (NASDAQ:BIIB)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for BIIB
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- rjw225: $ARDX $NVO $LLY $BIIB interesting IBD article regarding these tickers: https://www.investors.com/news/technology/eli-lilly-stock-buy-now/?src=A00220
- bhaden1: @rjw225 $ARDX $NVO $LLY $BIIB Very negative article on CNBC PRO stating all of the drug makers who may be effected by Ozempic's new wonder drug application. Was released at 10 a.m. EST. Explains the selling...again..
- woodman: @bhaden1 $ARDX $NVO $LLY $BIIB - $XBI is wrecked.
- camaro69: $BIIB Maybe? small
- Henry: $BIIB Halted on FDA hearing for Alzheimers drug. Gotlieb thinks it will be approved.
- scottrades: $BIIB Halted as FDA advisory panel meets to discuss Alzheimer's drug
- scottrades: @scottrades $BIIB Or, sorry just saw your post @Henry
- Henry: $BIIB got approval for the Alzheimers drug, the stock has been halted all day. np
- woodman: $BMRN (weekly view is nice) and $BIIB - breakouts. More generally, $IBB is trying too.
-
Rockstar: ...
The $DIA and $IWM continue their strength with some strength in more than a couple ETF's. The ETF's that I am looking at long positions include $TAN, $XLF, $XLE, $XLB, $XLI, $XLP, $XLV, $XME,and $IYT. Of these, I am hesitant on the $XLE with oi ... - woodman: $BIIB new high (highest since Sept 2021). Moving higher into January PDUFA for mild/early Alzheimer's drug (followed by one for a different drug in April 2023).
- woodman: $BIIB - I've been holding this and plan to continue to hold it with the thought that it will continue to rise into its 1/6/23 PDUFA (FDA approval) for its early Alzheimer's biologic lecanemab. It's partner on this, btw, is Japanese company $ESALY.
- jonwest88: $LLY still looks good on this mild pullback. Truist raised their target to $421 from $400. Roche's failure with its Alzheimer's drug has other "betting" still on $LLY and $BIIB. $LLY has that anti obesity drug coming. Take a pill and lose 20 lbs or more. Hmm, wonder how much that drug will cost? What price vanity or not having to change one's unhealthy life style?
- woodman: $BIIB getting a pop this morning on a P3 failure of Roche's Alzheimer's drug, leaving BIIB and Eisai as the front runners in this therapeutic area. BIIB recently had good news, as seen in the chart in Sept. (Long BIIB.)
- woodman: $BIIB - trying to extend move out of its 1.3 month range following a big gap up. I think this continues the upward path in the coming days and weeks.
- woodman: $BIIB - moving up out of its 1.5-month post-news (re Alzheimer's drug candidate which resulted in a big gap up in late Sept) range.
- woodman: $BIIB - this one had big news in late Sept about its Phase 3 trial for its early Alzheimer's drug. It moved up significantly. It's now testing the top of the post-news range. https://investors.biogen.com/news-releases/news-release-details/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary
-
Rockstar: ...
Lastly, I am looking at the $XBI and while $BIIB is looking to make new highs I am focusing in on $$APLS, and $VRTX . Will look closer at $VRTX as it has reported earnings and $APLS has not. I do like the set up in $APLS as it is right at the 8,2 ... - scottrades: Some #Earnings to be aware of this week: $AAPL $AMZN $MSFT $META $GOOGL $UPS $SHOP $GM $KO $BA $CLF $F $PHG $XOM $HAL $INTC $GE $VLO $MMM $ENPH $V $JBLU $CVX $CMG $BOH $RTX $AJG $DORM $MCD $CAT $WM $LUV $MA $SHW $PINS $SCHN $BMY $MRK $BIIB $ADM $X $SPOT $KEX $KHC $DX
- kycol: My #danscan-with-a-sqz shown only 2 green stocks: $BIIB & $KR
- jonwest88: @Painter $LLY It's $BIIB 's drug that showed a 27% decrease in A symptoms over a 3 year study. $BIIB is halted on the news
- Roadrunner: $BIIB $LLY beam me up scotty
- scottrades: @Roadrunner $BIIB $LLY Wow, news related?
- bla00109: @scottrades $BIIB $LLY Yes, BIIB's drug, lecanemab, showed positive result in delaying Alzheimer's disease. I still am looking to find out where the study is published because I would like to review. BIIB's other drug, Aduhelm, has been generally rejected by the neurologic community as likely ineffective. ( BIIB canceled their post release surveillance trial for Aduhelm because of the poor uptake by neurologic community, which led Biden administration to reduce Medicare premiums for next year.)
-
DAN: ...
$BIIB -- This is what you want to see in a basing phase. Way too early here.
$LLY -- Tightening up here. But this isn’t buyable here. Alert $325
$MRO -- Alert $27.80
$AKRO -- Huge power move. ONLY buy at a new high. Alert $30
$AZPN -- Wait ... - lrbarton: $biib Biogen above 20 and 50 close to a break above 200 building a base
-
DAN: ...
One chart that represents the type of thing I'm looking for is Biogen ($BIIB). I'll go over it in this morning's Option Market Mentor training session, which will be open to all members. (Be mindful, however, that the content will be devoted to op ... - gmj: $BIIB, $ALNY, $EXEL, $NRIX, $IMGN all wkng abv 50ma today long $BIIB, $LABU tight stops
- vfr777: $BIIB at 50day and making a higher low - 1st resistance 20week $226.65. Would like to see it break there.
- bRobert: @vfr777 $BIIB 20WEEK ceiling speed bump now Patience if you like Many speed bumps
-
DAN: ...
$BIIB -- Looking like it’s starting a move out of a short base.
-
twinvest: $SAVA $LLY $BIIB
$SAVA treating AD via their single drug candidate Simulfilam and possible future competition to $LLY $BIIB $PFE in the AD market
summary from their website:
Simulfilam targets the altered Filamin A protein in the brain which interact ... - bla00109: $LLY $BIIB - Recent CMS news about coverage of Alzheimer's amyloid antibody drugs - going to be restricted to clinical trials. CMS proposes to: --Use a Coverage with Evidence Development to further study the drug. Amyloid therapies will only be covered by Medicare in the context of CMS-approved randomized controlled trials or trials supported by the NIH -- Restrict trials to hospital-based outpatient facilities -- Require trials to meet diversity and inclusion standards to ensure traditionally underrepresented populations are not excluded -- Allow for one PET scan for amyloid in the patient’s lifetime to be performed on participating patients to confirm amyloid positivity -- Apply the coverage determination to all amyloid monoclonal antibody therapies for the treatment of AD, not just aducanumab. Multiple therapies within the same class are working through the approval process right now
- Pokersmith: @bla00109 $LLY $BIIB and your conclusion as it relates to $LLY ?
- bla00109: @Pokersmith $LLY $BIIB The same CMS ruling will apply to Solanezumab -- the LLY monoclonal antibody which is in developement. None of these agents will be widely available for a while. I don't think that any of antibody drugs impact earnings/revenue in 2022. But I may be wrong.
- Pokersmith: @bla00109 $LLY $BIIB No, you are correct. Virtually no impact on earnings or revenues this year, at most , about $153 million according to consensus estimates. Eli Lilly’s donanemab is superior to Biogen’s Aduhelm, and what will add conviction in their treatment is the data from the ongoing Phase 3 TRAILBLAZER-ALZ 2 study. The readout of this study is a catalyst event that should help the industry better understand how its benefits outweigh the risks. The readout of this study is expected in the first half of 2023 and according to JPMorgan analysts, Eli Lilly believes a successful phase 3 readout will address any reimbursement hurdles. >>source: AAP<< Thx for the response 👍
- Pokersmith: Re: Alduhem The drug was approved by the Food and Drug Administration in June in a decision criticized by many experts because clinical trials showed it had significant safety risks and unclear benefit to patients. Whether Medicare ends up covering Aduhelm is considered pivotal to the future of the drug, which is priced at $28,200 a year per patient. See: $BIIB Np
- debeers: $BIIB-One advantage in getting up in the middle of the night here is you get to make a 600 buck mistake instead of a 1700 dollar one as Samsung denies any interest in BIIB purchase. This was in a regulatory filing. Guess i can cross the Korea Times off of the sources to be believed list.
- bRobert: @debeers $BIIB Yesterday was a sell the news event As is most news
- debeers: @bRobert $BIIB -'cmon man. Hindsight is always 20-20. I have now done 5 of these "buyouts" and have made money on 4. The last was the Tiffany one and, because LVMUY had lusted after it for years, it seemed very credible to me. That was a huge win as i already held $TIF stock.
- Carpe_Diem: $BIIB - Biogen shares are trading higher following a Korea Economic Daily Global Edition report titled 'Samsung Group in negotiations to buy Biogen.'
- woodman: @Carpe_Diem $BIIB - and this was back in September. Related? https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11
- Carpe_Diem: @woodman $BIIB - Where there is smoke ....... Short Term options volume spiked up today.
- champ: @woodman $BIIB --- Yes that was the FDA approval....however now todays News is that the Samsung Group #is in talks, this new News today confirms, that negotiations are underway to buy #BIIB,....everything, old and new, all sounds positive.
- bRobert: @woodman $BIIB Big speed bump Expect a pullback Better entry
- woodman: @bRobert $BIIB - No way would I touch BIIB now. Np.
- bRobert: @woodman $BIIB That post wasn't for you ;) Breakouts are ALERTS to get your attention To follow Most are sold into and lead to better low risk entries
- woodman: @bRobert $BIIB 👍
- roddog101: @debeers $BIIB got lucky on it today, saw it starting to pop & thought something was up, grabbed some then the news started to hit on twatter. Got about 18 bucks from it but was only 250 shares.
- debeers: @roddog101 $BIIB -congrats! i waited for the close AFTER i looked at what WAS the BIIB premium at the high. Samsung wouldn't have to pay nearly that but shareholders will have a very nice New Year with 17% up from here. So we'll see.
- debeers:
- Pokersmith: @roddog101 $BIIB Wow !!..definitely didn't see THIS happening....Samsung??? 🤔 🤷♂️ Nice pull, congrats 👍
- champ: @Pokersmith $BIIB ....Just turn the lights-on, that way you can See better, in real time, not lag-time. Hit 'Em Straight. LOL
- Babutters: @debeers $BIIB it’s crazy to see how on the monthly it’s been flagging for 8 years. Granted an extremely wide spread (220-400). Glad to pick some up on the bottom of the flag.
- woodman: @debeers $BIIB https://www.investors.com/news/technology/biogen-stock-surge-report-suggests-samsung-interested-in-a-buyout/
- achiever: @brobert good place to start position in $BIIB?
- bRobert: @achiever $BIIB NO Bear flag bounce to $240 You missed that nimble trade Why even touch it now ? It CAN hit $200 Not for my $$$
- jsdpie: Bloomberg: $ANTM and $BIIB improved forecast
- woodman: $BIIB - after a huge spike up in June followed by a sustained pullback, it's been consolidating and edging higher for weeks just under the rising 50d, following under it closely. In the last few days, the 50d finally turned down after digesting the big spike up. Price is now moving up above the 50d, and the 8dEMA is about to cross above the 50d. This one may slowly continue to grind higher.
- woodman: $BIIB interesting. It's forming a big base/bowl, but hasn't been able to get above the rising 50 day over the last month. But over the last 3 weeks, it has been holding the rising 8dEMA. The weekly shows a clearer rise since around mid July with good room to potentially move back up.
- Momentariness: $BIIB LOD looking shaky
- scottto_2: #InsideBarList - My OCD kicked in hard on this one - Thanks Sir @Aragorn - $AAL $AAOI $AAPL $ABC $ABT $ABUS $ACAD $ADI $ADS $AEM $AES $AFL $AGCO $AGIO $AIG $AKAM $AKTX $ALE $ALGT $AMCX $AMN $AMP $AMT $AMZN $AN $ANET $ANGI $ANTM $AON $APA $APD $APRN $ ...
- Wykeman: $BIIB had earnings this am. vol coming in. low risk reward imo
- Henry: @scottto_2 $MRNA like the $BIIB drug for Alzheimers? ;-)
- debeers: @Henry $MRNA $BIIB -i am very concerned about the Moderna one. Supposedly there is a pericarditis issue as a side effect. When/if i ever have an inflamed heart it better not be from an illness. Of course, compared to Guilanne Barre----geez!
- woodman: @debeers $MRNA $BIIB - Pfizer version is mRNA too. In US, there've been about 1,050 cases out of hundreds of millions of doses administered. Mostly in male adolescents and young adults age 16 years or older, but connection to mRNA vaccines is still being investigated. With Delta variant causing numbers to spike again, and unvaccinated people making up 99% of the covid deaths, I'm 100% fine with my decision to get vaccinated.
- debeers: @woodman $MRNA $BIIB -Well Woody, after consulting with Bo this morning, i am 99% sure i got the right one too(moderna)..
- woodman: @debeers $MRNA $BIIB :-)
- jvee: The FDA is looking into the $BIIB alzheimer drug causing both $SAVA and $ANVS to tank. SAVA may have stopped dropping. ANVS may be close.
- Mnatale: $BIIB mentioned yesterday, working this morning.
- lostsheep: $BIIB weekly reversal
- Mnatale: @indigo1948 $SAVA oddly enough I have a smidge of $BIIB the first one to get FDA approval on Alzheimer drug.. its doing well today after being hammered with bad news on the appalling price they are charging for treatment... guess everyone is jumping on the FDA band wagon for this now...
- bla00109: $BIIB " Aduhelm (Biogens Alzheimer's drug) approval was far from unanimous and in fact, controversial enough that three members of a Food and Drug Administration advisory committee have now resigned in protest. The latest resignation of Harvard Medical School professor Aaron Kesselheim, who called the Aduhelm approval "probably the worst drug approval decision in recent U.S. history," follows the resignations of David Knopman, a neurologist at the Mayo Clinic, and Joel Perlmutter, a neurologist at Washington University in St. Louis." -- Cramer's comment today.
- bla00109: @champ $LLY $LLY's Alzheimer drug might be more convincingly effective (based on the recent published phase2 trial) compared to $BIIB drug (where clinical effectiveness was questionable). In my opinion, I don't think $BIIB should have been approved. Therefore, the approval of the $LLY drug by the FDA is likely if phase 3 trial confirms positive results from the phase 2 trial. But, as I've post before, the pipeline drug, tirzepitide, for diabetes and weight loss will be a monster..
- champ: @bla00109 $LLY $BIIB ---- Thanks Doc and I have been following your posts...
- joelsg1: $BIIB Alzheimer drug approved, halted but upside explosion due momentarily.
- dagdog: @joelsg1 $BIIB Such great news!!!!
- traderbren: $XBI - punching through the 200 dma overhead....on the back on $BIIB news.
- bRobert: @traderbren $XBI $BIIB $LABU. $85. target $XBI was setting up with. tight consolidation pinch
- Mnatale: can anyone confirm if the $BIIB is still in Halt mode?
- scottto_2: @Mnatale $BIIB - yes (as of 12:18 EDT)
- bla00109: $LLY $BIIB I am honestly surprised to see the FDA greenlight Adacanmab, the $BIIB Alzheimer's monoclonal Ab treatment. Based on my reading of their trial, I didn't think Adacanmab was very effective. The two Adacanmab phase 3 trials were contradictory and the results were inconclusive at best. On the other hand, the recent phase 2 trial of Donanemab (the $LLY antibody) did show statical benefit . $LLY up 12.6% today in concert. I expect that $LLY' s drug will be approved also. I'm in $LLY long term for other things in their pipeline. (Namely, Tirzepetide looks like an amazing diabetes drug and probably the best weight loss potential of any oral or injectable therapy).
- joelsg1: @bla00109 $LLY $BIIB Trading again, up 160.
- bla00109: @joelsg1 $BIIB trading above 4 SD above 20 d MA. That's nuts. Possible 60 minute trade tomorrow AM. Like to see what @Dan says about this.
- bla00109: $BIIB Oh God!!! I'm already had my first patient wanting me to treat him with Adacanumab. I expect my front desk is about to be inundated by phone calls.
- stairm01: @bla00109 $BIIB Just human nature if you need help to try anything that will help the cause.
- Forexpro: @bla00109 $BIIB Thanks, Bla00109, This one was kind of a binary, with quite a few informed observers leaning toward the view that the drug wouldn't be approved. So, this is a legitimate surprise. The Rand Corp, which did a study admittedly commissioned by $BIIB, estimated the initial market size as 2.4 mio, with an estimated treatment cost of $30k. Even if there are some rounding errors, that's a pretty big number (details via Bloomberg.com). I love selling into ephemeral strength, but these are strange times. Tough short, it seems to me, but if I was long, I'd be selling with both hands. Already 60 bucks off the intraday high. Be lucky!
- Roadrunner: $PRTA $DNLI $ATHA up on $BIIB news
- scottto_2: @bRobert - $BIIB - What do you think. Other opinions welcome as well, of course!
- scottto_2: $BIIB - Weekly chart shows the story/potential. Thus the inquiry to @bRobert....
- bRobert: @scottto_2 $BIIB That is one messy chart. with. many speed. bumps.on the daily as well I would. watch it if you like. I. think there are easier places to. make money. right. now Focus on. stocks making the new high. list Look at their WEEKLY. charts to estimate measured moves Look for. pullback. bounces to enter. Stocks making new 52 week. highs tend to repeat. Select the best of the best They may have a long way to. go. Technically. unleashed. No resistance and a long term chart that projects much higher. targets. I look through the bargain. bin but am very selective and have a long time frame You field a team with the strongest players You may take an ocassional flyer on one that had reconstructive surgery
- scottto_2: @bRobert $BIIB - Thanks for the thoughts!
- Roadrunner: $SAGE reported. Clinical trials look promising for multiple studies in areas such as depression, essential tremors, parkinsons and other neurological disorders. Collaborating with $BIIB. Ran up 5.98% today. Up in after hours.
- 1winkie: Earnings today - $ABBV, $EBAY, $PYPL, $SPOT, $MET, $ IAC, $APO, $SAVE, $ELF, $BIIB, $YUMC, $HUM, $QCOM and $QRVO.
- scottrades: Some #Earnings to be aware of this week: $AMZN $BABA $PFE $UPS $PINS $PYPL $SNAP $GOOGL $XOM $F $QCOM $TMO $PTON $ABBV $APPS $SPOT $ON $ATVI $CLX $BMY $BP $GILD $CMG $EA $OTIS $EBAY $QTNT $NXPI $FEYE $VRTX $SIRI $CRUS $MRK $PLUS $LGND $BIIB $PENN $HOG $ARLP $MDC $REGN
- traderdl: $BIIB nice and steady +8% today
- Ajax4Hire: Yes, $MRNA-Moderna(a CoronaVirus vaccine developer) is in the $IBB. Looks like $MRNA, $NVCR and $TECH is the real reason $IBB looks so appealing. Hold% $IBB iShares Nasdaq Biotechnology ETF - Top 15 holdings 7.31% $GILD Gilead Sciences, Inc. 7.13% $AMGN Amgen Inc. 6.02% $VRTX Vertex Pharmaceuticals Incorporated 5.63% $REGN Regeneron Pharmaceuticals, Inc. 4.70% $ILMN Illumina, Inc. 4.62% $MRNA Moderna, Inc. 3.45% $BIIB Biogen Inc. 3.09% $SGEN Seagen, Inc. 2.89% $ALXN Alexion Pharmaceuticals, Inc. 1.90% $INCY Incyte Corporation 1.61% $HZNP Horizon Therapeutics Public Limited Company 1.56% $ALNY Alnylam Pharmaceuticals, Inc 1.52% $BMRN BioMarin Pharmaceutical Inc. 1.26% $NVCR NovoCure Ltd. 1.25% $TECH Bio-Techne Corporation Data from: https://ETFdB.com/etf/IBB/#holdings
- funfl: $BIIB ....kinda surprisingly no bounce in this one at all ..........just yet
- Motorman: $BIIB wow, NP gladly
-
DAN: ...
$BIIB -- can’t do anything with this.
| Stock Price | $146.47 |
| Change | -0.62% |
| Volume | 5,775,630 |
Biogen Idec Inc., is a global biotechnology company that discovers, develops, manufactures and markets therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia.
Request Video of BIIBAlready a member? Sign in here.
Past Month
Leading Peers
-
$8.10 261.95%
-
$9.45 124.91%
-
$16.98 106.56%
Past Month
Lagging Peers
-
$9.73 %
-
$17.03 -115.10%
-
$35.42 -44.96%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!